Tesamorelin safety, side effects and monitoring

Safety profile

Injection-site reactions, joint pain, muscle pain, peripheral oedema and — significantly — glucose intolerance. Tesamorelin can worsen blood-sugar control, which matters a great deal in a population that overlaps with metabolic disease. It is contraindicated in active malignancy, pituitary disorders and pregnancy. Fasting glucose and HbA1c should be monitored.

Monitoring

A legitimate programme establishes a baseline before it ships anything. For Tesamorelin, ask what will be measured before you start, at what interval it will be re-measured, and what result would indicate the treatment is not working — a provider who cannot answer the last question has no plan for stopping.

Questions to ask

1. Am I receiving FDA-approved Egrifta, or a compounded preparation? They are not the same thing.
2. Do I actually have the indication it is approved for?
3. How will my blood glucose and HbA1c be monitored?
4. What is the evidence for my specific goal, as opposed to the approved one?
5. What happens when I stop?

Questions to ask about the pharmacy

The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.

1. Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
2. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
3. In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
4. What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
5. Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
6. Will you provide a certificate of analysis?
7. Has the pharmacy received any FDA warning letter or state board action?

A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.